JP2014518552A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014518552A5 JP2014518552A5 JP2014505586A JP2014505586A JP2014518552A5 JP 2014518552 A5 JP2014518552 A5 JP 2014518552A5 JP 2014505586 A JP2014505586 A JP 2014505586A JP 2014505586 A JP2014505586 A JP 2014505586A JP 2014518552 A5 JP2014518552 A5 JP 2014518552A5
- Authority
- JP
- Japan
- Prior art keywords
- phenoxy
- ethyl
- methylsulfonyl
- fluoro
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 14
- OYFWJMHZQZMCIM-UHFFFAOYSA-N n-phenoxyethanamine Chemical class CCNOC1=CC=CC=C1 OYFWJMHZQZMCIM-UHFFFAOYSA-N 0.000 claims 12
- 150000001204 N-oxides Chemical class 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 208000035475 disorder Diseases 0.000 claims 8
- -1 2 -cyclopropyl Chemical group 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000012661 Dyskinesia Diseases 0.000 claims 5
- 201000000980 schizophrenia Diseases 0.000 claims 5
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 4
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 206010012289 Dementia Diseases 0.000 claims 3
- 208000023105 Huntington disease Diseases 0.000 claims 3
- 208000028017 Psychotic disease Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000014094 Dystonic disease Diseases 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 206010034010 Parkinsonism Diseases 0.000 claims 2
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims 2
- 208000016620 Tourette disease Diseases 0.000 claims 2
- 208000029560 autism spectrum disease Diseases 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 208000010118 dystonia Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- BHCSEBZPESSXOJ-UHFFFAOYSA-N n-[2-(3-fluoro-5-methylsulfonylphenoxy)ethyl]butan-1-amine Chemical compound CCCCNCCOC1=CC(F)=CC(S(C)(=O)=O)=C1 BHCSEBZPESSXOJ-UHFFFAOYSA-N 0.000 claims 2
- OSBPYFBXSLJHCR-UHFFFAOYSA-N n-[2-(3-fluoro-5-methylsulfonylphenoxy)ethyl]propan-1-amine Chemical compound CCCNCCOC1=CC(F)=CC(S(C)(=O)=O)=C1 OSBPYFBXSLJHCR-UHFFFAOYSA-N 0.000 claims 2
- BQEQVMXYMOVUTM-UHFFFAOYSA-N n-ethyl-2-(3-fluoro-5-methylsulfonylphenoxy)ethanamine Chemical compound CCNCCOC1=CC(F)=CC(S(C)(=O)=O)=C1 BQEQVMXYMOVUTM-UHFFFAOYSA-N 0.000 claims 2
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- XBIWYCHIWQDRHO-UHFFFAOYSA-N 1-(3-fluoro-5-methylsulfonylphenoxy)-n-propylpropan-2-amine Chemical compound CCCNC(C)COC1=CC(F)=CC(S(C)(=O)=O)=C1 XBIWYCHIWQDRHO-UHFFFAOYSA-N 0.000 claims 1
- ULYYLRLQSVQDKI-UHFFFAOYSA-N 1-[2-(3-fluoro-5-methylsulfonylphenoxy)ethyl]azetidine Chemical compound CS(=O)(=O)C1=CC(F)=CC(OCCN2CCC2)=C1 ULYYLRLQSVQDKI-UHFFFAOYSA-N 0.000 claims 1
- QPJKPHFTNUZUON-UHFFFAOYSA-N 1-[2-(3-fluoro-5-methylsulfonylphenoxy)ethyl]piperidine Chemical compound CS(=O)(=O)C1=CC(F)=CC(OCCN2CCCCC2)=C1 QPJKPHFTNUZUON-UHFFFAOYSA-N 0.000 claims 1
- DLKVQLABRDFMNP-UHFFFAOYSA-N 2-(3-fluoro-5-methylsulfonylphenoxy)-n-propylpropan-1-amine Chemical compound CCCNCC(C)OC1=CC(F)=CC(S(C)(=O)=O)=C1 DLKVQLABRDFMNP-UHFFFAOYSA-N 0.000 claims 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 206010020852 Hypertonia Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 206010044565 Tremor Diseases 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 206010008129 cerebral palsy Diseases 0.000 claims 1
- HFXKQSZZZPGLKQ-UHFFFAOYSA-N cyclopentamine Chemical compound CNC(C)CC1CCCC1 HFXKQSZZZPGLKQ-UHFFFAOYSA-N 0.000 claims 1
- 229960003263 cyclopentamine Drugs 0.000 claims 1
- 230000010249 dopaminergic function Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000002545 drug psychosis Diseases 0.000 claims 1
- 208000035474 group of disease Diseases 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- RFWUHUYECRPDDQ-UHFFFAOYSA-N n,n-diethyl-2-(3-fluoro-5-methylsulfonylphenoxy)ethanamine Chemical compound CCN(CC)CCOC1=CC(F)=CC(S(C)(=O)=O)=C1 RFWUHUYECRPDDQ-UHFFFAOYSA-N 0.000 claims 1
- BHOCMEYROOUQKX-UHFFFAOYSA-N n-(cyclopropylmethyl)-2-(3-fluoro-5-methylsulfonylphenoxy)ethanamine Chemical compound CS(=O)(=O)C1=CC(F)=CC(OCCNCC2CC2)=C1 BHOCMEYROOUQKX-UHFFFAOYSA-N 0.000 claims 1
- DUYQHEGMZVGKEE-UHFFFAOYSA-N n-[2-(3-chloro-5-methylsulfonylphenoxy)ethyl]propan-1-amine Chemical compound CCCNCCOC1=CC(Cl)=CC(S(C)(=O)=O)=C1 DUYQHEGMZVGKEE-UHFFFAOYSA-N 0.000 claims 1
- AWBCNMJTPXEZIZ-UHFFFAOYSA-N n-[2-(3-fluoro-5-methylsulfonylphenoxy)ethyl]-2-methylbutan-2-amine Chemical compound CCC(C)(C)NCCOC1=CC(F)=CC(S(C)(=O)=O)=C1 AWBCNMJTPXEZIZ-UHFFFAOYSA-N 0.000 claims 1
- SRCFIFBVUFTTSZ-UHFFFAOYSA-N n-[2-(3-fluoro-5-methylsulfonylphenoxy)ethyl]-2-methylpropan-1-amine Chemical compound CC(C)CNCCOC1=CC(F)=CC(S(C)(=O)=O)=C1 SRCFIFBVUFTTSZ-UHFFFAOYSA-N 0.000 claims 1
- XZOYYKQMPMTMBE-UHFFFAOYSA-N n-[2-(3-fluoro-5-methylsulfonylphenoxy)ethyl]-n-methylpropan-1-amine Chemical compound CCCN(C)CCOC1=CC(F)=CC(S(C)(=O)=O)=C1 XZOYYKQMPMTMBE-UHFFFAOYSA-N 0.000 claims 1
- LDGSLDGDBLBRDR-UHFFFAOYSA-N n-[2-(3-fluoro-5-methylsulfonylphenoxy)ethyl]butan-2-amine Chemical compound CCC(C)NCCOC1=CC(F)=CC(S(C)(=O)=O)=C1 LDGSLDGDBLBRDR-UHFFFAOYSA-N 0.000 claims 1
- ODFVMTOLMMHTSY-UHFFFAOYSA-N n-[2-(3-fluoro-5-methylsulfonylphenoxy)ethyl]propan-2-amine Chemical compound CC(C)NCCOC1=CC(F)=CC(S(C)(=O)=O)=C1 ODFVMTOLMMHTSY-UHFFFAOYSA-N 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161476810P | 2011-04-19 | 2011-04-19 | |
| DKPA201170187 | 2011-04-19 | ||
| DKPA201170187 | 2011-04-19 | ||
| US61/476,810 | 2011-04-19 | ||
| DKPA201170495 | 2011-09-06 | ||
| DKPA201170495 | 2011-09-06 | ||
| PCT/EP2012/056959 WO2012143337A1 (en) | 2011-04-19 | 2012-04-17 | Novel modulators of cortical dopaminergic- and nmda-receptor-mediated glutamatergic neurotransmission |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014518552A JP2014518552A (ja) | 2014-07-31 |
| JP2014518552A5 true JP2014518552A5 (enExample) | 2015-04-16 |
| JP5876140B2 JP5876140B2 (ja) | 2016-03-02 |
Family
ID=47041067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014505586A Active JP5876140B2 (ja) | 2011-04-19 | 2012-04-17 | 皮質のドーパミン作動性及びｎｍｄａ受容体介在のグルタミン酸作動性神経伝達の新規なモジュレータ |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9006227B2 (enExample) |
| EP (1) | EP2699543B1 (enExample) |
| JP (1) | JP5876140B2 (enExample) |
| KR (1) | KR101964406B1 (enExample) |
| CN (1) | CN103476746B (enExample) |
| AU (1) | AU2012244867C1 (enExample) |
| CA (1) | CA2832874C (enExample) |
| DK (1) | DK2699543T3 (enExample) |
| ES (1) | ES2566634T3 (enExample) |
| IL (1) | IL228705A (enExample) |
| MX (1) | MX341847B (enExample) |
| PL (1) | PL2699543T3 (enExample) |
| RU (1) | RU2593500C2 (enExample) |
| SG (1) | SG193992A1 (enExample) |
| WO (1) | WO2012143337A1 (enExample) |
| ZA (1) | ZA201307227B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6789681B2 (ja) * | 2016-06-10 | 2020-11-25 | スリーエム イノベイティブ プロパティズ カンパニー | グラフィックフィルム、ライセンスプレート、及びグラフィックフィルムの製造方法 |
| WO2020239568A1 (en) * | 2019-05-24 | 2020-12-03 | Integrative Research Laboratories Sweden Ab | Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof |
| EP4125840A1 (en) | 2020-03-27 | 2023-02-08 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of synucleinopathies |
| EP4243801A1 (en) | 2020-11-10 | 2023-09-20 | Integrative Research Laboratories Sweden AB | [2-(3-fluoro-5-methanesulfonylphenoxy)ethyl](propyl)amine (mesdopetam) for use in the prevention or reduction of sensitization to a pharmaceutical drug for parkinson's disease, in particular l-dopa induced dyskinesias |
| WO2024042540A1 (en) * | 2022-08-24 | 2024-02-29 | Alkem Laboratories Limited | Mesdopetam compositions |
| EP4590657A1 (en) | 2022-09-21 | 2025-07-30 | Assia Chemical Industries Ltd. | Solid state forms of mesdopetam and salts therof |
| GB202312055D0 (en) | 2023-08-07 | 2023-09-20 | Ipsen Biopharm Ltd | Pharmaceutical compositions |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS51123821A (en) | 1975-04-18 | 1976-10-28 | Nippon Kayaku Co Ltd | An algicide and protective agent |
| IL87181A (en) * | 1987-08-07 | 1993-08-18 | Sanofi Sa | Aminoalkoxyphenyl derivatives, their preparation and pharmaceutical and veterinary compositions containing them |
| GB8823405D0 (en) | 1988-10-05 | 1988-11-09 | Erba Carlo Spa | Aryloxy-arythio-heteraryloxy-heteroarylthio-alkenylene derivatives of amines |
| SI0707007T1 (en) | 1994-10-14 | 2002-04-30 | Merck Patent Gmbh | (R)-(-)-2-(5-(4-fluorophenyl)-3-pyridylmethylaminomethyl)chromane as CNS active agent |
| DOP2001000189A (es) * | 2000-06-30 | 2002-03-30 | Pfizer Prod Inc | Benzofenonas y sulfonas como inhibidores de la captación de glicina |
| GB0428235D0 (en) | 2004-12-23 | 2005-01-26 | Glaxo Group Ltd | Novel compounds |
| JP2006193494A (ja) | 2005-01-17 | 2006-07-27 | Dainippon Ink & Chem Inc | ４級アンモニウム系化合物を有効成分とする心臓疾患治療剤 |
| WO2007063789A1 (ja) | 2005-11-29 | 2007-06-07 | Kissei Pharmaceutical Co., Ltd. | 新規なカテコール誘導体、それを含有する医薬組成物およびそれらの用途 |
| WO2007072041A1 (en) * | 2005-12-23 | 2007-06-28 | Astex Therapeutics Limited | Therapeutic compounds |
| CA2642630A1 (en) * | 2006-02-15 | 2007-08-30 | M's Science Corporation | Piperazine derivatives |
| EP2271635A1 (en) | 2008-04-29 | 2011-01-12 | NSAB, Filial af NeuroSearch Sweden AB, Sverige | Modulators of dopamine neurotransmission |
| DK2271634T3 (da) | 2008-04-29 | 2014-05-05 | Integrative Res Lab Sweden Ab | Modulatorer af dopamin-neurotransmission |
| MX2010011498A (es) | 2008-04-29 | 2010-11-12 | Nsab Af Neurosearch Sweden Ab | Moduladores de neurotransmision de dopamina. |
-
2012
- 2012-04-17 JP JP2014505586A patent/JP5876140B2/ja active Active
- 2012-04-17 DK DK12714704.9T patent/DK2699543T3/en active
- 2012-04-17 WO PCT/EP2012/056959 patent/WO2012143337A1/en not_active Ceased
- 2012-04-17 PL PL12714704.9T patent/PL2699543T3/pl unknown
- 2012-04-17 ES ES12714704.9T patent/ES2566634T3/es active Active
- 2012-04-17 CN CN201280019006.2A patent/CN103476746B/zh active Active
- 2012-04-17 KR KR1020137030198A patent/KR101964406B1/ko active Active
- 2012-04-17 EP EP12714704.9A patent/EP2699543B1/en active Active
- 2012-04-17 MX MX2013012025A patent/MX341847B/es active IP Right Grant
- 2012-04-17 SG SG2013072871A patent/SG193992A1/en unknown
- 2012-04-17 RU RU2013147917/04A patent/RU2593500C2/ru active
- 2012-04-17 CA CA2832874A patent/CA2832874C/en active Active
- 2012-04-17 US US14/112,080 patent/US9006227B2/en active Active
- 2012-04-17 AU AU2012244867A patent/AU2012244867C1/en active Active
-
2013
- 2013-10-03 ZA ZA2013/07227A patent/ZA201307227B/en unknown
- 2013-10-03 IL IL228705A patent/IL228705A/en active IP Right Grant
-
2015
- 2015-01-23 US US14/603,661 patent/US9120728B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014518552A5 (enExample) | ||
| RU2470011C2 (ru) | Циклоалкиламины, содержащие в качестве заместителя фенил, как ингибиторы обратного захвата моноаминов | |
| RU2430913C2 (ru) | Циклоалкиламины в качестве ингибиторов повторного поглощения моноамина | |
| RU2012127770A (ru) | Полициклические соединения и способы их применения | |
| JP6155280B2 (ja) | フェニルアルキルカルバメート誘導体化合物およびこれを含む薬学組成物 | |
| RU2013147917A (ru) | Новые модуляторы кортикальной дофаминергической и опосредованной nmda-рецептором глутаматергической нейротрансмиссии | |
| JP2018104454A5 (enExample) | ||
| RU2016131875A (ru) | Производные n-фениллактама, способные стимулировать нейрогенез, и их применение при лечении заболеваний нервной системы | |
| CN1706813A (zh) | 含长链脂肪酰基取代的文拉法辛前体药物及其制备方法和用途 | |
| JP2011518858A5 (enExample) | ||
| RU2018130727A (ru) | Органические соединения | |
| JP2014051526A5 (enExample) | ||
| JP2009527462A5 (enExample) | ||
| JP2014520072A5 (enExample) | ||
| JP2013512926A5 (enExample) | ||
| JP2014526469A5 (enExample) | ||
| JP2018505204A5 (enExample) | ||
| JP2020517607A5 (enExample) | ||
| JP2014507455A5 (enExample) | ||
| JP2016514117A5 (enExample) | ||
| JP2019512469A5 (enExample) | ||
| RU2015112914A (ru) | Бензимидазолы в качестве активных агентов для центральной нервной системы | |
| RU2018134262A (ru) | Производное 5-этил-4-метил-пиразол-3-карбоксамида, обладающее активностью агониста taar | |
| JP2016504992A5 (enExample) | ||
| JP2018508592A5 (enExample) |